scholarly journals Geometric Flow Control Lateral Flow Immunoassay Devices (GFC-LFIDs): A New Dimension to Enhance Analytical Performance

Research ◽  
2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
E. Eriksson ◽  
J. Lysell ◽  
H. Larsson ◽  
K. Y. Cheung ◽  
D. Filippini ◽  
...  
Keyword(s):  
Flow Control ◽  
Large Scale ◽  
Limit Of Detection ◽  
Point Of Care ◽  
Fold Increase ◽  
Lateral Flow ◽  
Analytical Performance ◽  
Lateral Flow Immunoassay ◽  
Geometric Flow ◽  
Novel Approach

The nitrocellulose (NC) membrane based lateral flow immunoassay device (LFID) is one of the most important and widely used biosensor platforms for point-of-care (PoC) diagnostics. However, the analytical performance of LFID has limitations and its optimization is restricted to the bioassay chemistry, the membrane porosity, and the choice of biolabel system. These bottom neck technical issues resulted from the fact that the conventional LFID design principle has not evolved for many years, which limited the LFID for advanced biosensor applications. Here we introduce a new dimension for LFID design and optimization based on geometric flow control (GFC) of NC membranes, leading to highly sensitive GFC-LFID. This novel approach enables comprehensive flow control via different membrane geometric features such as the width (w) and the length (l) of a constriction, as well as its input angle (θ1) and output angle (θ2). The GFC-LFID (w=0.5 mm, l=7 mm, θ1= 60°, θ2= 45°) attained a 10-fold increase in sensitivity for detection of interleukin-6 (IL-6), compared with conventional LFID, whereas reducing by 10-fold the antibody consumption. The GFC-LFID detects IL-6 over a linear range of 0.1–10 ng/mL with a limit of detection (LoD) of 29 pg/mL, which even outperforms some commercial IL-6 LFIDs. Such significant improvement is attained by pure geometric control of the NC membrane, without additives, that only relaying on a simple high throughput laser ablation procedure suitable for integration on regular large-scale manufacturing of GFC-LFIDs. Our new development on GFC-LFID with the combination of facile scalable fabrication process, tailored flow control, improved analytical performance, and reduced antibodies consumption is likely to have a significant impact on new design concept for the LFID industry.

scholarly journals Experiments And Simulations of Thermometric Lateral Flow Immunoassay For Point-of-Care Testing

2021 ◽  
Author(s):  
Terumitsu Azuma ◽  
Yuen Yung Hui ◽  
Oliver Y. Chen ◽  
Yuh-Lin Wang ◽  
Huan-Cheng Chang
Keyword(s):  
Laser Power ◽  
Limit Of Detection ◽  
Point Of Care ◽  
Lateral Flow ◽  
Detection Sensitivity ◽  
Lateral Flow Immunoassay ◽  
Point Of Care Testing ◽  
Incident Laser Power ◽  
Latex Beads ◽  
Fold Reduction

Abstract Temperature sensing is a promising method of enhancing the detection sensitivity of lateral flow immunoassay for point-of-care testing. A temperature increase of more than 100 °C can be readily achieved by photoexcitation of reporters like gold nanoparticles (GNPs) or colored latex beads (CLBs) on the strips with a laser power below 100 mW. Despite its promise, processes involved in the photothermal detection have not yet been well-characterized. Here, we provide a fundamental understanding of this thermometric assay by combining experiments and simulations using non-fluorescent CLBs as the reporters deposited on nitrocellulose membrane. By measuring the dependence of temperature rises on the number density of membrane-bound CLBs, we determined a 1.5-fold enhancement of the light absorption at 520 nm by the beads (diameter of 0.4 μm). The enhancement, however, was compromised by a 5-fold reduction of the incident laser power due to multiple scattering of the light in this highly porous medium. The limit of detection was measured to be 1 × 105 particles/mm2. In line with previous studies using GNPs as the reporters, the CLB-based thermometric assay provides a 10× higher sensitivity than color visualization, as demonstrated with the immunoassay for nucleocapsid proteins of the SARS-CoV-2 virus.

Rapid Detection of Shellfish Major Allergen Tropomyosin Using Superparamagnetic Nanoparticle-Based Lateral Flow Immunoassay

2011 ◽  
Vol 311-313 ◽  
pp. 436-445 ◽  
Author(s):  
Liang Shi ◽  
Xi Chang Wang ◽  
Yuan Liu ◽  
Ying Lu
Keyword(s):  
Limit Of Detection ◽  
Point Of Care ◽  
High Specificity ◽  
Major Allergen ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Quantitative Detection ◽  
Point Of Care Test ◽  
Western Blot Method ◽  
Food Species

In this study, a competitive assay format using superparamagnetic nanoparticle-based lateral flow immunoassay (LFIA) was developed for rapid, quantitative detection of shellfish major allergen tropomyosin (Tm). Sartorius CN140 nitrocellulose membrane and 0.05mg/mL Tm immobilized in the test line (T line) were optimized in order to improve the performance of the LFIA system. Calibration curves for Tm under PBS-T diluents and carp muscle extraction diluents were established. Limit of detection (LOD) for Tm calibrated by carp muscle matrix was 12.4ng/mL with a work range of 0.01 to 20μg/mL. According to magnetic signals change with the time of sample flowing on the strip, the qualitative time of the LFIA was about 10min, while the quantitative time of the LFIA was about 25min. 30 food species were detected separately by the LFIA and Western blot method to evaluate the specificity of the LFIA. Overall relative agreement of the two methods was 96.7% (29/30). Moreover, intra- and inter-assay precisions of the LFIA for Tm detection were <10.20% and <12.34%, respectively. The average recovery range in different food matrices was 80.3~111.8%, within a reasonable range. Our data confirmed that the superparamagnetic nanoparticle-based LFIA method developed in this study is rapid, simple, high specificity and capable of quantitative test. Consequently, the LFIA has the potential application in the field of point-of-care test of shellfish major allergen Tm.

A Point of Care Lateral Flow Assay for Rapid and Colorimetric Detection of Interleukin 6 and Perspectives in Bedside Diagnostics

2020 ◽  
Author(s):  
Carla Eiras
Keyword(s):  
Interleukin 6 ◽  
Limit Of Detection ◽  
Inflammatory Diseases ◽  
Point Of Care ◽  
Colorimetric Detection ◽  
Lateral Flow ◽  
Lateral Flow Assay ◽  
Aggregation Assay ◽  
Before And After ◽  
Bedside Diagnosis

Interleukin-6 (IL-6) is a multifunctional cytokine and high bloodstream levels of which have been associated with severe inflammatory diseases, such as dengue fever, sepsis, various cancers, and visceral leishmaniasis (VL). Rapid tests for the quantification of IL-6 would be of great assistance for the bedside diagnosis and treatment of diseases such as VL. We have developed a lateral flow assay (LFA) for rapid and colorimetric IL-6 detection, consisting of anti-IL-6 antibodies conjugated to gold nanoparticles (AuNPs). The optimal concentration of anti-IL-6 used in the conjugate was determined to be 800.0 μg/mL, based on an aggregation assay using LFA. A linear relationship between IL-6 standard concentration and color intensity was observed after 20 min, with a linear range between 1.25 ng/mL and 9,000 ng/mL. The limit of detection for this method was estimated a t0.38 ng/mL. The concentration of IL-6 in five patients with severe VL was measured using LFA, and the results were consistent with those obtained using the cytometric bead array (CBA) method. A thorough analysis of the LFA membranes’ surface morphology, before and after sample contact, was performed using atomic force microscopy (AFM).The prototype described here is still being tested and improved, but this LFA will undoubtedly be of great help in the clinical quantification of IL-6.

A Point of Care Lateral Flow Assay for Rapid and Colorimetric Detection of Interleukin 6 and Perspectives in Bedside Diagnostics

2020 ◽  
Author(s):  
Carla Eiras
Keyword(s):  
Interleukin 6 ◽  
Limit Of Detection ◽  
Inflammatory Diseases ◽  
Point Of Care ◽  
Colorimetric Detection ◽  
Lateral Flow ◽  
Lateral Flow Assay ◽  
Aggregation Assay ◽  
Before And After ◽  
Bedside Diagnosis

Interleukin-6 (IL-6) is a multifunctional cytokine and high bloodstream levels of which have been associated with severe inflammatory diseases, such as dengue fever, sepsis, various cancers, and visceral leishmaniasis (VL). Rapid tests for the quantification of IL-6 would be of great assistance for the bedside diagnosis and treatment of diseases such as VL. We have developed a lateral flow assay (LFA) for rapid and colorimetric IL-6 detection, consisting of anti-IL-6 antibodies conjugated to gold nanoparticles (AuNPs). The optimal concentration of anti-IL-6 used in the conjugate was determined to be 800.0 μg/mL, based on an aggregation assay using LFA. A linear relationship between IL-6 standard concentration and color intensity was observed after 20 min, with a linear range between 1.25 ng/mL and 9,000 ng/mL. The limit of detection for this method was estimated at a t0.38 ng/mL. The concentration of IL-6 in five patients with severe VL was measured using LFA, and the results were consistent with those obtained using the cytometric bead array (CBA) method. A thorough analysis of the LFA membranes’ surface morphology, before and after sample contact, was performed using atomic force microscopy (AFM). The prototype described here is still being tested and improved, but this LFA will undoubtedly be of great help in the clinical quantification of IL-6.

Upconversion nanoparticles-based lateral flow immunoassay for point-of-care diagnosis of periodontitis

2021 ◽  
Vol 334 ◽  
pp. 129673
Author(s):  
Wanghong He ◽  
Minli You ◽  
Zedong Li ◽  
Lei Cao ◽  
Feng Xu ◽  
...  
Keyword(s):  
Point Of Care ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Upconversion Nanoparticles

scholarly journals Integrating high-performing electrochemical transducers in lateral flow assay

2021 ◽  
Author(s):  
Antonia Perju ◽  
Nongnoot Wongkaew
Keyword(s):  
High Performance ◽  
Point Of Care ◽  
Low Cost ◽  
High Sensitivity ◽  
Lateral Flow ◽  
Analytical Performance ◽  
Label Free ◽  
High Performing ◽  
Lateral Flow Assays ◽  
Electrochemical Transducers

AbstractLateral flow assays (LFAs) are the best-performing and best-known point-of-care tests worldwide. Over the last decade, they have experienced an increasing interest by researchers towards improving their analytical performance while maintaining their robust assay platform. Commercially, visual and optical detection strategies dominate, but it is especially the research on integrating electrochemical (EC) approaches that may have a chance to significantly improve an LFA’s performance that is needed in order to detect analytes reliably at lower concentrations than currently possible. In fact, EC-LFAs offer advantages in terms of quantitative determination, low-cost, high sensitivity, and even simple, label-free strategies. Here, the various configurations of EC-LFAs published are summarized and critically evaluated. In short, most of them rely on applying conventional transducers, e.g., screen-printed electrode, to ensure reliability of the assay, and additional advances are afforded by the beneficial features of nanomaterials. It is predicted that these will be further implemented in EC-LFAs as high-performance transducers. Considering the low cost of point-of-care devices, it becomes even more important to also identify strategies that efficiently integrate nanomaterials into EC-LFAs in a high-throughput manner while maintaining their favorable analytical performance.

scholarly journals Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis

2020 ◽  
Vol 58 (9) ◽  
Author(s):  
Katharina Ziegler ◽  
Anca Rath ◽  
Christoph Schoerner ◽  
Renate Meyer ◽  
Thomas Bertsch ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Roc Curve ◽  
Point Of Care ◽  
Lateral Flow ◽  
Lyme Neuroborreliosis ◽  
Diagnostic Tools ◽  
Lateral Flow Immunoassay ◽  
Enzyme Linked Immunosorbent Assay ◽  
European Federation ◽  
Point Of Care Test

ABSTRACT Diagnosis of Lyme neuroborreliosis (LNB) is challenging, as long as Borrelia-specific intrathecal antibodies are not yet detectable. The chemokine CXCL13 is elevated in the cerebrospinal fluid (CSF) of LNB patients. Here, we compared the performances of the Euroimmun CXCL13 enzyme-linked immunosorbent assay (CXCL13 ELISA) and the ReaScan CXCL13 lateral flow immunoassay (CXCL13 LFA), a rapid point-of-care test, to support the diagnosis of LNB. In a dual-center case-control study, CSF samples from 90 patients (34 with definite LNB, 10 with possible LNB, and 46 with other central nervous system [CNS] diseases [non-LNB group]) were analyzed with the CXCL13 ELISA and the CXCL13 LFA. Classification of patients followed the European Federation of Neurological Societies (EFNS) guidelines on LNB. The CXCL13 ELISA detected elevated CXCL13 levels in all patients with definite LNB (median, 1,409 pg/ml) compared to the non-LNB controls (median, 20.7 pg/ml; P < 0.0001), with a sensitivity of 100% and a specificity of 84.8% (cutoff value, 78.6 pg/ml; area under the receiver operating characteristic [ROC] curve, 0.93). Similarly, the CXCL13 LFA yielded elevated CXCL13 levels in 31 patients with definite LNB (median arbitrary value, 223.5) compared to the non-LNB control patients (median arbitrary value, 0; P < 0.0001) and had a sensitivity and specificity of 91.2% and 93.5%, respectively (cutoff arbitrary value, 22.5; area under the ROC curve, 0.94). The correlation between the CXCL13 levels obtained by ELISA and LFA was strong (Spearman correlation coefficient r = 0.89; P < 0.0001). The CXCL13 ELISA and the CXCL13 LFA are comparable diagnostic tools for the detection of CXCL13 in the CSF of patients with definite LNB. The advantage of the CXCL13 LFA is the shorter time to result.

scholarly journals Multi-Quantum Dots-Embedded Silica-Encapsulated Nanoparticle-Based Lateral Flow Assay for Highly Sensitive Exosome Detection

Nanomaterials ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 768
Author(s):  
Hyung-Mo Kim ◽  
Chiwoo Oh ◽  
Jaehyun An ◽  
Seungki Baek ◽  
Sungje Bock ◽  
...  
Keyword(s):  
Quantum Dots ◽  
Limit Of Detection ◽  
Specific Binding ◽  
Calf Serum ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Uniform Size ◽  
Highly Sensitive ◽  
Wide Range ◽  
New Biomarkers

Exosomes are attracting attention as new biomarkers for monitoring the diagnosis and prognosis of certain diseases. Colorimetric-based lateral-flow assays have been previously used to detect exosomes, but these have the disadvantage of a high limit of detection. Here, we introduce a new technique to improve exosome detection. In our approach, highly bright multi-quantum dots embedded in silica-encapsulated nanoparticles (M–QD–SNs), which have uniform size and are brighter than single quantum dots, were applied to the lateral flow immunoassay method to sensitively detect exosomes. Anti-CD63 antibodies were introduced on the surface of the M–QD–SNs, and a lateral flow immunoassay with the M–QD–SNs was conducted to detect human foreskin fibroblast (HFF) exosomes. Exosome samples included a wide range of concentrations from 100 to 1000 exosomes/µL, and the detection limit of our newly designed system was 117.94 exosome/μL, which was 11 times lower than the previously reported limits. Additionally, exosomes were selectively detected relative to the negative controls, liposomes, and newborn calf serum, confirming that this method prevented non-specific binding. Thus, our study demonstrates that highly sensitive and quantitative exosome detection can be conducted quickly and accurately by using lateral immunochromatographic analysis with M–QD–SNs.

Sign in / Sign up

Export Citation Format

Share Document